Cocrystal pharma presentation at the reimagine health research symposium features overview of platform technology and four antiviral case studies

Bothell, wash., jan. 21, 2021 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp), (“cocrystal” or the “company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the sars-cov-2 virus, hepatitis c viruses and noroviruses, provides the following summary of today's upcoming presentation by cocrystal president sam lee, ph.d. at the virtual 3rd annual reimagine health research symposium, university of arizona college of medicine. a live webcast of dr. lee's presentation, titled “application of structure-based drug design platform technology for developing broad spectrum, covid-19, influenza, and hcv antivirals,” will be available at 9:50 a.m. pacific time (12:50 p.m. eastern time) by registering here . dr. lee's presentation will be available on the cocrystal website here beginning friday, january 22, 2021.
COCP Ratings Summary
COCP Quant Ranking